This study will evaluate the efficacy and safety of DA-9701 in patients with functional dyspepsia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
Severance Hospital
Seoul, South Korea
RECRUITINGChanges in GIS(Gastrointestinal Symptom Score) total scores
Time frame: Change from baseline at 4 weeks
Changes in GIS(Gastrointestinal Symptom Score) total scores
Time frame: Change from baseline at 2 weeks
Changes in GIS(Gastrointestinal Symptom Score) scores by symptoms
Time frame: Change from baseline at 2 weeks and 4 weeks
Changes in NDI-K QoL(Nepean Dyspepsia Index-Korean version Quality of Life) domain scores and total scores
Time frame: Change from baseline at 4 weeks
Subject's global assessment
Time frame: at week 4
Investigator's global assessment
Time frame: at week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1 tablet, TID